Mike Moyer is an Investor Relations professional at LifeSci Advisors, involved in significant financing and clinical trial projects for psoriasis treatment.
Mike Moyer's Title
Mike Moyer holds the pivotal role of Investor Relations at LifeSci Advisors. In this capacity, he is responsible for maintaining and enhancing communication between the company and its investors. His expertise in finance and strategic communication ensures that investor queries are addressed promptly and transparently, fostering trust and confidence among stakeholders.
Mike Moyer's Company
Mike Moyer works at LifeSci Advisors, a prominent life sciences consultancy firm that provides a broad range of strategic and financial advisory services to healthcare companies. LifeSci Advisors is known for its deep industry knowledge and comprehensive suite of services, including corporate communications, investor relations, and capital markets advisory. Mike's role within the firm underscores his importance in driving investor relations and facilitating critical financial transactions.
Mike Moyer's Achievements
One of Mike Moyer's significant achievements includes his involvement in a bridge financing of $4.5 million led by North South Ventures. This strategic financial move was instrumental in ensuring the continued growth and development of the company, showcasing Mike's ability to secure crucial funding. Additionally, Mike played a key role in announcing the positive results from the SFA-002 Phase 1b cohort 1 clinical trial for the treatment of mild-to-moderate psoriasis. This milestone demonstrated the therapeutic potential of SFA-002, an oral pill acting on multiple pathways to modulate the immune response by down-regulating pro-inflammatory cytokines.
Mike Moyer's Background
With a strong background in investor relations and financial strategy, Mike Moyer has established himself as a vital asset to LifeSci Advisors. His expertise in managing investor communications and securing funding has been critical to the company's success. Mike's involvement in the development and clinical trials of innovative treatments, such as SFA-002 for psoriasis, highlights his commitment to advancing healthcare solutions and improving patient outcomes.